FGFR1 and non-small cell lung carcinoma: We also reviewed the records of NSCLC patients on regorafenib, a multikinase inhibitor that blocks FGFR1 and 2 and various other receptors, and pazopanib, a multikinase inhibitor that blocks FGFR, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor, but did not find any cases similar to those of the three patients on FGFR inhibitors.